查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1965361

全球医药玻璃包装市场－产业规模、份额、趋势、机会及预测：依产品、药品类型、地区及竞争格局划分，2021-2031年

Pharmaceutical Glass Packaging Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Vials, Bottles, Cartridges & Syringes, Ampoules), By Drug Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球医药玻璃包装市场预计将从 2025 年的 210.7 亿美元成长到 2031 年的 294.8 亿美元，复合年增长率为 5.76%。

该行业的特点是专门生产使用硼硅酸或钠钙玻璃製成的初级容器，例如管瓶、安瓿瓶、药筒和注射器，以确保药品的无菌性和化学稳定性。市场成长的根本动力来自全球慢性病注射治疗需求的不断上升，以及学名药行业的蓬勃发展，后者对可靠且受监管的储存方式提出了更高的要求。除了暂时的市场波动外，这些持续成长要素凸显了玻璃无与伦比的不渗透性和化学惰性的重要性。这些特性对于保护复杂的生物製药和疫苗免受环境污染至关重要。

市场概览
预测期 2027-2031
市场规模：2025年 210.7亿美元
市场规模：2031年 294.8亿美元
复合年增长率：2026-2031年 5.76%
成长最快的细分市场 瓶子
最大的市场 北美洲

儘管成长前景可观，但由于玻璃材料本身的易碎性，市场仍面临许多挑战。与聚合物替代品相比，玻璃在高速灌装、表面处理工程中容易破损，导致营运成本增加，安全风险也更高。儘管如此，在主要的高科技製造地区，玻璃产业依然保持着强劲的经济成长动能。德国玻璃工业协会（Bundesverband Glasindustrie eV）的数据也印证了这种韧性。该协会报告称，到2024年，对製药应用至关重要的实用玻璃和特殊玻璃领域的收入将成长6.4%，达到18.2亿欧元。

市场驱动因素

对需要特殊玻璃的生物製药和生物相似药的需求不断增长，正在推动市场价值链的根本性变革，并对先进的密封系统提出了更高的要求。与传统的小分子药物不同，单株抗体和GLP-1促效剂等复杂的生物製药对錶面相互作用高度敏感，因此高品质的I型硼硼硅酸玻璃对于防止分层和确保化学稳定性至关重要。这种需求正促使市场从标准通用管瓶转向高价值解决方案（HVS），例如预填充式注射器和涂层药筒，这些产品具有更强的抗破损能力。这种向高端容器的转变也体现在主要产业参与者的财务表现中。例如，萧特製药（SCHOTT Pharma）于2024年12月发布的《2024年度报告》显示，高价值解决方案的营收成长了22%，占公司总会计收入的55%。

同时，新兴经济体医药市场的快速扩张是推动销售成长的重要因素，与已开发地区以价值驱动的成长形成互补。在政府鼓励供应链本地化的指导指南以及非专利注射剂市场强劲增长的推动下，印度和中国等国正积极扩大其国内医药生产能力。这种地理多元化迫使全球玻璃製造商建立本地製造地，以最大限度地降低供应链风险并缩短前置作业时间。康宁公司和SGD Pharma的合资企业就是这项策略的显着例证，Chemindigest在2025年9月对此进行了通报。两家公司在印度投资500卡罗尔印度卢比，建立了一家生产药用级硼硅酸玻璃管的工厂。此类投资凸显了该产业的持续经济实力，Gerresheimer AG在2025年2月发布的报告也进一步印证了这一点，该报告显示，其2024财年的集团合併收入达到20.4亿欧元。

市场挑战

阻碍医药玻璃包装产业发展的主要障碍在于玻璃材料本身固有的脆弱性。与高耐久性的聚合物替代品相比，玻璃容器在高速填充和表面处理工程中以及物流运输中极易破损。这种破损会导致昂贵药物的即时损失，并需要耗费大量成本进行生产线清洗，从而显着增加营运成本。因此，製造商在运输易损生物製药时面临更高的责任风险，并被迫将玻璃的使用限制在对化学惰性要求绝对严格的必要应用中。

这种脆弱性所带来的经济影响在市场规模趋势中得到了清楚的体现。在非专业领域，玻璃容器难以与抗衝击替代品竞争。此外，微裂纹可能导致颗粒物污染，增加了监管合规的复杂性，限制了其在大规模生产的非专利注射剂领域的应用。玻璃包装协会2024年的数据显示，化妆品、药品和盥洗用品的玻璃容器总合出货量占美国玻璃容器市场总量的比例仍低于1%，这印证了上述量化限制。这些数据表明，物理特性限制了玻璃容器的应用范围，使其只能局限于高价值的小众市场，而无法获得广泛的量化优势。

市场趋势

即用型 (RTU)管瓶的加速普及优化了生产流程，无需内部清洁和灭菌步骤。这一趋势使得填充和包装生产线能够灵活地管理小批量生产，与批量生产相比，从而降低了整体拥有成本。 RTU 平台将包装准备和药物填充流程分离，显着降低了污染风险，并推动了向预灭菌系统的明确过渡。 Stevanato 集团于 2024 年 3 月发布的「2023 年第四季及全年财务表现」清晰地展示了这一转变，该报告显示，包括无菌容器系统在内的高价值解决方案的收入增长至占公司总会计收入的 34%。

同时，为支持永续性目标而转向轻质玻璃设计，强调透过优化形状和使用回收材料来减少碳排放。製造商正在开发熔化和运输所需能源更少的轻质管瓶，直接有助于实现范围3的排放目标。这一趋势支持使用环保玻璃配方，这些配方既满足企业的ESG要求，又能保持化学稳定性。这种广泛应用是可以量化的。根据Bormioli Pharma于2024年4月发布的《2023年ESG报告》，该公司已成功将其产品中永续材料的比例提高到45%，比去年同期成长显着。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球医药玻璃包装市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 产品类别（管瓶（管瓶、大管瓶）、瓶子（小瓶、大瓶）、卡式註射器/注射器、安瓿瓶）
    • 药物类型（学名药、品牌名药物、生物製药）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美医药玻璃包装市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲医药玻璃包装市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区医药玻璃包装市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东与非洲医药玻璃包装市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲医药玻璃包装市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球医药玻璃包装市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Corning Incorporated
  • Heartsine Technologies, Inc.
  • Nipro Corporation
  • SGD SA
  • Stoelzle Oberglas GmbH
  • Bormioli Pharma SpA
  • West Pharmaceutical Services, Inc.
  • Schott AG
  • Gerresheimer AG
  • Shandong Pharmaceutical Glass Co., Ltd.
  • Beatson Clark
  • Ardagh Group SA
  • Arab Pharmaceutical Glass Co.
  • Piramal Enterprises Ltd.
  • SiSecam Group
  • Owens-Illinois, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23465

The Global Pharmaceutical Glass Packaging Market is projected to expand from USD 21.07 Billion in 2025 to USD 29.48 Billion by 2031, registering a CAGR of 5.76%. This sector is characterized by the specialized production of primary containment vessels, such as vials, ampoules, cartridges, and syringes, utilizing borosilicate or soda-lime glass to guarantee drug sterility and chemical stability. The market's fundamental growth is propelled by the rising global incidence of chronic conditions necessitating injectable treatments and the vigorous development of the generic medicine industry, which demands reliable, regulatory-compliant storage. These enduring drivers, separate from temporary market fluctuations, highlight the essential dependence on glass for its unmatched impermeability and chemical inertness, attributes that are vital for protecting complex biologics and vaccines from environmental contamination.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 21.07 Billion
Market Size 2031USD 29.48 Billion
CAGR 2026-20315.76%
Fastest Growing SegmentBottles
Largest MarketNorth America

Despite this positive growth outlook, the market faces a significant obstacle due to the inherent fragility of the material; glass breakage during high-speed fill-finish processes and transport leads to higher operational costs and safety hazards when compared to polymer substitutes. Nonetheless, the industry sustains robust economic momentum within major high-tech manufacturing territories. This resilience is evidenced by data from the Bundesverband Glasindustrie e.V., which reported that in 2024, the utility and special glass sector-a crucial segment for pharmaceutical uses-saw revenue increase by 6.4 percent, totaling EUR 1.82 billion.

Market Driver

The escalating demand for biologics and biosimilars requiring specialized glass is fundamentally transforming the market's value chain by mandating advanced containment systems. Unlike conventional small-molecule medications, intricate biologics like monoclonal antibodies and GLP-1 agonists exhibit high sensitivity to surface interactions, necessitating high-quality Type I borosilicate glass to avoid delamination and guarantee chemical stability. This necessity has driven a migration from standard commoditized vials toward High-Value Solutions (HVS), such as prefilled syringes and coated cartridges, which provide enhanced inertness and resistance to breakage. The pivot toward premium containment is reflected in the financial results of leading industry players; for example, SCHOTT Pharma's 'Annual Report 2024', released in December 2024, noted that revenue from high-value solutions rose by 22 percent, comprising 55 percent of its total fiscal revenue.

Concurrently, the rapid expansion of pharmaceutical markets in emerging economies serves as a crucial volume driver, complementing the value-focused growth seen in developed regions. Nations like India and China are aggressively building domestic pharmaceutical manufacturing capacities, aided by government directives for supply chain localization and the strong growth of the generic injectables market. This geographic diversification forces global glass producers to create local manufacturing centers to minimize supply chain risks and shorten lead times. A prominent instance of this strategy is cited by Chemindigest in September 2025, detailing a joint venture between Corning Incorporated and SGD Pharma to open a facility in India with an INR 500 crore investment for producing pharmaceutical-grade borosilicate glass tubing. Such investments highlight the sector's ongoing economic strength, further supported by Gerresheimer AG's February 2025 report, which announced consolidated group revenues of EUR 2.04 billion for the 2024 financial year.

Market Challenge

The principal obstacle hindering the growth of the pharmaceutical glass packaging industry is the material's intrinsic fragility. In contrast to durable polymer alternatives, glass containers are prone to fracturing during intense high-speed fill-finish operations and logistical handling. Such breakage causes the immediate loss of expensive drug formulations and mandates expensive production halts for line clearance, thereby substantially increasing operational costs. As a result, manufacturers confront increased liability risks when transporting delicate biologics, forcing them to restrict glass utilization to essential applications where chemical inertness is absolute and non-negotiable.

The economic repercussions of this vulnerability are apparent in market volume trends, where glass faces difficulty competing with shatter-resistant substitutes in non-specialized categories. The potential for particulate contamination arising from micro-cracks further adds to regulatory compliance complexities, limiting adoption within the mass-market generic injectables sector. Underscoring this volume constraint, data from the Glass Packaging Institute in 2024 indicated that the combined shipment share for cosmetics, pharmaceuticals, and toiletries accounted for less than 1 percent of the total United States glass container market. This statistic demonstrates how physical limitations restrict the material to a high-value niche, precluding it from achieving broader dominance in volume.

Market Trends

The accelerating adoption of sterile Ready-to-Use (RTU) glass vials is optimizing manufacturing processes by removing the need for in-house washing and sterilization. This trend enables fill-finish lines to manage smaller batch sizes with enhanced flexibility, thereby lowering the total cost of ownership relative to bulk processing. By separating packaging preparation from drug filling, RTU platforms significantly reduce contamination risks, driving a definitive move toward pre-sterilized systems. This transition is highlighted by the Stevanato Group's 'Fourth Quarter and Full Year 2023 Financial Results' from March 2024, which reported that revenue from the high-value solutions segment, encompassing sterile containment systems, grew to represent 34 percent of the company's total fiscal revenue.

Simultaneously, the shift toward lightweight glass designs to support sustainability goals is emphasizing carbon reduction through the use of optimized geometries and recycled materials. Manufacturers are developing lighter vials that demand less energy for melting and transportation, directly contributing to meeting Scope 3 emission targets. This movement validates the use of eco-friendly glass formulations that retain chemical stability while satisfying corporate ESG requirements. The extent of this adoption is quantifiable; as per Bormioli Pharma's 'ESG Report 2023' released in April 2024, the company successfully raised the proportion of sustainable materials in its sold products to 45 percent, indicating a substantial expansion compared to the previous year.

Key Market Players

  • Corning Incorporated
  • Heartsine Technologies, Inc.
  • Nipro Corporation
  • SGD S.A.
  • Stoelzle Oberglas GmbH
  • Bormioli Pharma S.p.A.
  • West Pharmaceutical Services, Inc.
  • Schott AG
  • Gerresheimer AG
  • Shandong Pharmaceutical Glass Co., Ltd.
  • Beatson Clark
  • Ardagh Group S.A
  • Arab Pharmaceutical Glass Co.
  • Piramal Enterprises Ltd.
  • SiSecam Group
  • Owens-Illinois, Inc.

Report Scope

In this report, the Global Pharmaceutical Glass Packaging Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Glass Packaging Market, By Product

  • Vials (Small vials, Large vials)
  • Bottles(Small bottles, Large bottles)
  • Cartridges & Syringes
  • Ampoules

Pharmaceutical Glass Packaging Market, By Drug Type

  • Generic
  • Branded
  • Biologic

Pharmaceutical Glass Packaging Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Glass Packaging Market.

Available Customizations:

Global Pharmaceutical Glass Packaging Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Glass Packaging Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Vials (Small vials, Large vials), Bottles(Small bottles, Large bottles), Cartridges & Syringes, Ampoules)
    • 5.2.2. By Drug Type (Generic, Branded, Biologic)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Pharmaceutical Glass Packaging Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Drug Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharmaceutical Glass Packaging Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Drug Type
    • 6.3.2. Canada Pharmaceutical Glass Packaging Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Drug Type
    • 6.3.3. Mexico Pharmaceutical Glass Packaging Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Drug Type

7. Europe Pharmaceutical Glass Packaging Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Drug Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharmaceutical Glass Packaging Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Drug Type
    • 7.3.2. France Pharmaceutical Glass Packaging Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Drug Type
    • 7.3.3. United Kingdom Pharmaceutical Glass Packaging Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Drug Type
    • 7.3.4. Italy Pharmaceutical Glass Packaging Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Drug Type
    • 7.3.5. Spain Pharmaceutical Glass Packaging Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Drug Type

8. Asia Pacific Pharmaceutical Glass Packaging Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Drug Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pharmaceutical Glass Packaging Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Drug Type
    • 8.3.2. India Pharmaceutical Glass Packaging Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Drug Type
    • 8.3.3. Japan Pharmaceutical Glass Packaging Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Drug Type
    • 8.3.4. South Korea Pharmaceutical Glass Packaging Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Drug Type
    • 8.3.5. Australia Pharmaceutical Glass Packaging Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Drug Type

9. Middle East & Africa Pharmaceutical Glass Packaging Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Drug Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pharmaceutical Glass Packaging Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Drug Type
    • 9.3.2. UAE Pharmaceutical Glass Packaging Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Drug Type
    • 9.3.3. South Africa Pharmaceutical Glass Packaging Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Drug Type

10. South America Pharmaceutical Glass Packaging Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Drug Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharmaceutical Glass Packaging Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Drug Type
    • 10.3.2. Colombia Pharmaceutical Glass Packaging Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Drug Type
    • 10.3.3. Argentina Pharmaceutical Glass Packaging Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Drug Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pharmaceutical Glass Packaging Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Corning Incorporated
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Heartsine Technologies, Inc.
  • 15.3. Nipro Corporation
  • 15.4. SGD S.A.
  • 15.5. Stoelzle Oberglas GmbH
  • 15.6. Bormioli Pharma S.p.A.
  • 15.7. West Pharmaceutical Services, Inc.
  • 15.8. Schott AG
  • 15.9. Gerresheimer AG
  • 15.10. Shandong Pharmaceutical Glass Co., Ltd.
  • 15.11. Beatson Clark
  • 15.12. Ardagh Group S.A
  • 15.13. Arab Pharmaceutical Glass Co.
  • 15.14. Piramal Enterprises Ltd.
  • 15.15. SiSecam Group
  • 15.16. Owens-Illinois, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer